Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month. Read more in Cancer […]

read more

Stereotactic radiosurgery is successful for RCC brain metastases

A recent study of 362 patients with brain metastases from renal cell carcinoma (RCC) were treated with stereotactic radiosurgery to remove the metastases. The researchers concluded that stereotactic radiosurgery is highly effective in patients with brain metastases from RCC, and concomitant use of tyrosine kinase inhibitors (TKIs), such as sunitinib and pazopanib, does not suggest […]

read more

Complete response of kidney cancer brain metastases to cabozantinib

A recent case study, reported in Case Reports in Urology, presented an unusual case of a patient with metastatic renal cell carcinoma (RCC) and brain metastases who experienced a complete response to cabozantinib prior to radiation therapy. This case study contributes to the limited evidence on the activity of cabozantinib within the brain. The researchers […]

read more

Stereotactic radiosurgery for multiple kidney cancer brain metastases

A recent study published in Clinical Genitourinary Cancer has shown that stereotactic radiosurgery (SRS) is effective for controlling renal cell carcinoma (RCC) brain metastases, although the effectiveness of SRS is not so good with larger metastatic tumours. In the study, more than half of the patients treated with SRS survived beyond a year, and there were […]

read more

ESMO 2018: Assessment of asymptomatic brain metastases in kidney cancer patients

The results of an analysis of renal cell carcinoma (RCC) patients with brain metastases that were not causing any symptoms (asymptomatic metastatses) from the phase 2 GETUG-AFU 26 (NIVOREN) clinical trial were presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich last week. The GETUG-AFU 26 (NIVOREN) trial looked at the […]

read more

Nivolumab reduces brain metastases volume in some kidney cancer patients

A recent study by researchers from the Gustave Roussy Cancer Campus in Villejuif, France, and lead by Dr Bernard Escudier, reported preliminary data from a small group of patients with renal cell carcinoma (RCC) and brain metastases treated with nivolumab. The study showed that nivolumab shrinks brain tumour volume in 23% of such patients. Dr Escudier said “This is the […]

read more
Showing 11 to 16 of 16 results